US Bancorp’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-4,559
Closed -$27K 4309
2021
Q3
$27K Buy
+4,559
New +$28.4K ﹤0.01% 2978
2019
Q1
Sell
-131
Closed -$1K 3688
2018
Q4
$1K Hold
131
﹤0.01% 3550
2018
Q3
$2K Hold
131
﹤0.01% 3524
2018
Q2
$3K Hold
131
﹤0.01% 3458
2018
Q1
$3K Hold
131
﹤0.01% 3452
2017
Q4
$3K Hold
131
﹤0.01% 3437
2017
Q3
$3K Hold
131
﹤0.01% 3389
2017
Q2
$3K Hold
131
﹤0.01% 3353
2017
Q1
$4K Hold
131
﹤0.01% 3284
2016
Q4
$2K Hold
131
﹤0.01% 3404
2016
Q3
$3K Hold
131
﹤0.01% 3308
2016
Q2
$2K Buy
+131
New +$1.65K ﹤0.01% 3420

US Bancorp's FLXN Position: Q4 2021 in Review

US Bancorp sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 4,559 shares — an estimated $27K sold.

US Bancorp first reported a position in FLXN in Q2 2016 and held it in 12 quarters. The position peaked at $27K in Q3 2021. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.

  • US Bancorp reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • US Bancorp sold 4,559 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $27K.
  • US Bancorp first reported a position in Flexion Therapeutics, Inc. in Q2 2016 and held it in 12 quarters.
  • US Bancorp's Flexion Therapeutics, Inc. position peaked at $27K in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.

Based on US Bancorp's 13F filing for Q4 2021, filed 11 Feb 2022.